Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 2

Status

Terminated 3Completed 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 4Genitourinary 3Gastrointestinal 2Tumor-Agnostic 1Sarcoma 1Other solid neoplasm 1Dermatologic 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 3Metastatic Non-Squamous Non-Small Cell Lung Cancer 1Lung Neoplasms 1Lung Diseases 1

Interventions

Carboplatin 335Pemetrexed 276Cisplatin 228Paclitaxel 193pembrolizumab 178Erlotinib Hydrochloride 173Docetaxel 154Gemcitabine 126Nivolumab 112Bevacizumab 112Radiotherapy 84Etoposide 68durvalumab 62atezolizumab 59Ipilimumab 51Radiosurgery 49osimertinib 42130-nm albumin-bound paclitaxel 40Afatinib 39Gefitinib 38Cetuximab 38Albumin-Bound Paclitaxel 37Taxes 32Vinorelbine 29Radiation 29Topotecan 28Drug Therapy 25Crizotinib 23Platinum 21Dexamethasone 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Has results × sitravatinib × Thoracic × Clear all
NCT03906071 2025-10-21

SAPPHIRE

Mirati Therapeutics Inc.

Phase 3 Completed
577 enrolled 22 charts
Thoracic

Metastatic Non-Squamous Non-Small Cell Lung Cancer

NCT04921358 2025-06-29

Tislelizumab in Combination With Sitravatinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

BeiGene

Phase 3 Terminated
377 enrolled 22 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04925986 2025-04-17

Sitravatinib Plus Pembrolizumab in Patients With Advanced Treatment-Naïve PD-L1+ Non-Squamous NSCLC

Yale University

Phase 2 Terminated
9 enrolled 15 charts
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms

NCT02954991 2024-04-22

Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Non-Small Cell Lung Cancer

Mirati Therapeutics Inc.

Phase 2 Terminated
161 enrolled 15 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡